All In Biotech

Free tool

FAERS Monitor: Elidel

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 021302 or its brand name (Elidel, Pimecrolimus). Reports on generic versions are filed under their own applications.

Reports

1,797

Serious

577

32% of reports

Hospitalization

199

Death reported

22

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • drug ineffective266
  • dermatitis atopic212
  • pruritus209
  • rash193
  • product use in unapproved indication131
  • dry skin111
  • eczema104
  • off label use103
  • injection site pain82
  • skin exfoliation80
  • erythema77
  • sleep disorder due to a general medical condition73
  • pain67
  • condition aggravated66
  • product dose omission issue65

Reports by year received

View as table
YearReports
20043
20052
20062
20075
20088
20092
20107
201119
20125
20139
201413
201510
201615
201717
201840
201985
2020102
2021172
2022200
2023296
2024274
2025269
2026242

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,362 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
sleep disorder due to a general medical conditionSignal7350.540.33,482
dermatitis atopicSignal21247.241.69,535
eczemaSignal10423.319.32,199
skin exfoliationSignal8011.19.0728
dry skinSignal1119.78.1867
pruritusSignal2096.45.6957
product use in unapproved indicationSignal1316.25.2571
rashSignal1935.24.5661
erythemaSignal774.43.5200
injection site painSignal823.12.5118
product dose omission issueSignal652.62.063
condition aggravatedSignal662.52.061
drug ineffectiveSignal2662.42.1222
off label use1031.41.111
pain671.31.04

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.